公开(公告)号：US20240336894A1

公开(公告)日：2024-10-10

申请号：US18402999

申请日：2024-01-03

申请人： Affiliated Hospital of Jiangsu University

发明人： Xuefeng Wang ,  Yongbin Ma

IPC分类号： C12N5/0786

CPC分类号： C12N5/0645 ,  C12N2500/02 ,  C12N2500/05 ,  C12N2500/30 ,  C12N2500/84 ,  C12N2509/00 ,  C12N2523/00 ,  C12N2527/00 ,  C12N2529/00

摘要： A simple and efficient method for separating migrasomes from macrophages is provided. The method separates migrasomes having a diameter range of 0.5 micrometers (μm) to 3 μm by intercepting through a filter and eluting through reverse filtration successfully. The separated migrasome has a vesicle-liked structure and wrinkles on its surface, and the separated migrasome has a diameter over 500 nanometers (nm). The separated migrasomes express their characteristic proteins PIGK, EOGT, and TSPAN4, but do not express specific markers TSG101 and ALIX of EVs, indicating that the separated migrasomes are a unique type of vesicles distinct from extracellular vesicles (EVs). The integrity of ribonucleic acids (RNA) carried by the migrasomes is not affected. The method for separating migrasomes from macrophages has the characteristics of simplicity, high efficiency, good controllability, good repeatability, and low cost, and large special equipment is not needed.

公开(公告)号：US20240319170A1

公开(公告)日：2024-09-26

申请号：US18275125

申请日：2021-02-05

申请人： PRECEDO PHARMACEUTICALS CO., LTD

发明人： Qingsong LIU ,  Yuying HE ,  Cheng CHEN ,  Tao HUANG ,  Tao REN ,  Wenchao WANG ,  Li WANG

IPC分类号： G01N33/50 ,  C12N5/09

CPC分类号： G01N33/5011 ,  C12N5/0693 ,  C12N2500/02 ,  C12N2501/01 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/2322 ,  C12N2509/00

摘要： Disclosed are a culture medium and a culture method for in vitro expansion of primary cells of intestinal cancer. The culture medium comprises an initial culture medium, a Rho protease inhibitor, an antibiotic, gastrin, A8301, a non-essential amino acid, cholera toxin, an insulin-like growth factor-1, nicotinamide, insulin, fetal bovine serum, and an additive selected from at least one of a B27 additive and an N2 additive. By using the culture medium, effective and rapid expansion of the primary cells of intestinal cancer can be achieved. The expanded cells maintain the pathological characteristics of patients, and the culture success rate and the cell expansion rate of the primary cells of intestinal cancer are improved, which provide a research foundation for personalized treatment of the patients.

公开(公告)号：US20240301351A1

公开(公告)日：2024-09-12

申请号：US18662758

申请日：2024-05-13

申请人： CELL CURE NEUROSCIENCES LTD.

发明人： Osnat Bohana-Kashtan ,  Lior Ann Rosenberg Belmaker ,  Ofer Wiser

IPC分类号： C12N5/079 ,  A61K35/30

CPC分类号： C12N5/0621 ,  A61K35/30 ,  C12N2500/02 ,  C12N2500/38 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/16 ,  C12N2506/02 ,  C12N2533/52

摘要： A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.

公开(公告)号：US20240293468A1

公开(公告)日：2024-09-05

申请号：US18659833

申请日：2024-05-09

申请人： Figene, LLC

发明人： Pete O'Heeron ,  Thomas Ichim

IPC分类号： A61K35/33 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/715 ,  C12N5/077 ,  C12N7/00

CPC分类号： A61K35/33 ,  A61K39/0011 ,  A61K45/06 ,  A61P35/00 ,  C07K14/7158 ,  C12N5/0656 ,  C12N7/00 ,  A61K2039/585 ,  C12N2500/02 ,  C12N2710/24134 ,  C12N2710/24171

摘要： Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.

公开(公告)号：US12071612B2

公开(公告)日：2024-08-27

申请号：US17246365

申请日：2021-04-30

申请人： HEBEI MEDICAL UNIVERSITY

发明人： Bin Cong ,  Xianxian Jia

IPC分类号： C12N1/20 ,  C07K14/335 ,  C12P21/02 ,  A61K38/00 ,  C12R1/225

CPC分类号： C12N1/20 ,  C07K14/335 ,  C12P21/02 ,  A61K38/00 ,  C12N2500/02 ,  C12N2500/12 ,  C12N2500/16 ,  C12N2500/30 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2500/46 ,  C12N2500/74 ,  C12N2500/84 ,  C12R2001/225

摘要： The present disclosure relates to the technical field of microorganisms, in particular to Lactobacillus gasseri HMV18 and a secreted protein and an application thereof. The Lactobacillus gasseri HMV18 is preserved in the China Center for Type Culture Collection on Jul. 11, 2019 with a preservation number of CCTCC NO: M 2019538, and a preservation address of Wuhan University, Wuhan, China. The protein extracted from the Lactobacillus gasseri HMV18 has antibacterial and anti-tumor effects, but basically has no effect on normal myocardial cells, so the Lactobacillus gasseri HMV18 can be applied to preparation of antibacterial and anti-tumor products.

公开(公告)号：US12054740B2

公开(公告)日：2024-08-06

申请号：US17686811

申请日：2022-03-04

申请人： GROWGENE BIOTECH INC.

发明人： Pei-Chuan Chuang ,  Chin-Jing Huang

IPC分类号： A61K35/28 ,  A61K38/18 ,  A61K38/21 ,  C12N5/073 ,  C12N5/0775

CPC分类号： C12N5/0605 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/2318 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/415

摘要： The invention discloses a method for inhibiting the growth of cancer cells by use of an anti-cancer composition containing a conditioned cell culture medium from mesenchymal stem cells and cytokines. It comprises the steps of applying a composition with a conditioned cell culture medium from stem cells and at least one cytokine to cancer cells for growth inhibition of the cancer cells. The cell culture medium can be conditioned with Wharton's Jelly mesenchymal stem cells (WJMSCs) as an WJMSCs-conditioned cell culture medium, and the at least one cytokine is selected from a group consisting of bone morphogenetic protein-4, Dickkopf-related protein, Interferon-β and tumor necrosis factor-related apoptosis-inducing ligand.

公开(公告)号：US20240254441A1

公开(公告)日：2024-08-01

申请号：US18566518

申请日：2022-06-03

申请人： KIRIN HOLDINGS KABUSHIKI KAISHA

发明人： Shinichiro TAKAYANAGI ,  Ken FUKUMOTO

IPC分类号： C12N5/078

CPC分类号： C12N5/0634 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2502/45

摘要： An object of the present invention is to provide a technique for concentrating blood cells having high proliferation ability and/or differentiation ability. The present invention relates to a method for producing a cell composition, the method including: a step of extracting cells expressing a G protein-coupled receptor 56 (GPR56) from a cell aggregate containing immature blood cells, and a cell composition containing an immature blood cell expressing GPR56, in which a proportion of the immature blood cell expressing GPR56 is 50% to 100% of total cells.

公开(公告)号：US11987810B2

公开(公告)日：2024-05-21

申请号：US17546013

申请日：2021-12-08

申请人： Cell Cure Neurosciences Ltd.

发明人： Osnat Bohana-Kashtan ,  Lior Ann Rosenberg Belmaker ,  Ofer Wiser

IPC分类号： C12N5/079 ,  A61K35/30

CPC分类号： C12N5/0621 ,  A61K35/30 ,  C12N2500/02 ,  C12N2500/38 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/16 ,  C12N2506/02 ,  C12N2533/52

摘要： A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.

公开(公告)号：US11986498B2

公开(公告)日：2024-05-21

申请号：US14056101

申请日：2013-10-17

申请人： Osiris Therapeutics, Inc.

发明人： Timothy Jansen ,  Samson Tom ,  Alla Danilkovitch ,  Dana Yoo ,  Jaime Zerhusen

IPC分类号： A61K35/50 ,  A01N1/02 ,  A61K35/28 ,  A61K38/18 ,  A61K38/39 ,  A61K38/57 ,  C12N5/073

CPC分类号： A61K35/28 ,  A01N1/0221 ,  A61K35/50 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K38/57 ,  C12N5/0605 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2502/025

摘要： This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

公开(公告)号：US11959097B2

公开(公告)日：2024-04-16

申请号：US18226877

申请日：2023-07-27

申请人： Yeda Research and Development Co. Ltd.

发明人： Yaqub Hanna ,  Sergey Viukov ,  Emilie Wildschutz ,  Noa Novershtern ,  Carine Joubran ,  Segev Naveh Tassa ,  Alejandro Castrejon Aguilera ,  Bernardo Oldak ,  Shadi Tarazi ,  Francesco Roncato

IPC分类号： C12N5/073

CPC分类号： C12N5/0604 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/155 ,  C12N2501/415 ,  C12N2501/91 ,  C12N2501/999 ,  C12N2506/03

摘要： Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.